5-HIAA induces neprilysin to ameliorate pathophysiology and symptoms in a mouse model for Alzheimer’s disease

[1]  M. Pawłowski,et al.  Multi-Target-Directed Ligands Affecting Serotonergic Neurotransmission for Alzheimer's Disease Therapy: Advances in Chemical and Biological Research. , 2017, Current medicinal chemistry.

[2]  Gwenn S. Smith,et al.  Molecular imaging of serotonin degeneration in mild cognitive impairment , 2017, Neurobiology of Disease.

[3]  C. Dobson,et al.  Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. , 2017, Annual review of biochemistry.

[4]  J. Morris,et al.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials , 2017, Alzheimer's & Dementia.

[5]  P. Hof,et al.  Monoaminergic neuropathology in Alzheimer’s disease , 2017, Progress in Neurobiology.

[6]  J. Hopwood,et al.  Endo‐lysosomal and autophagic dysfunction: a driving factor in Alzheimer's disease? , 2017, Journal of neurochemistry.

[7]  J. Padmanabhan,et al.  Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer’s Disease , 2017, eNeuro.

[8]  E. Nollen,et al.  Cellular Regulation of Amyloid Formation in Aging and Disease , 2017, Front. Neurosci..

[9]  M. Szychlinska,et al.  Protective effects of high Tryptophan diet on aging-induced passive avoidance impairment and hippocampal apoptosis , 2017, Brain Research Bulletin.

[10]  Gilles J. Guillemin,et al.  Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases , 2017, Neuropharmacology.

[11]  D. Thomas,et al.  Brain imaging evidence of early involvement of subcortical regions in familial and sporadic Alzheimer's disease , 2017, Brain Research.

[12]  C. Eckman,et al.  Major amyloid-β–degrading enzymes, endothelin-converting enzyme-2 and neprilysin, are expressed by distinct populations of GABAergic interneurons in hippocampus and neocortex , 2016, Neurobiology of Aging.

[13]  Charalambos P. Kyriacou,et al.  L18 Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites , 2016 .

[14]  N. Hooper,et al.  Ablation of Prion Protein in Wild Type Human Amyloid Precursor Protein (APP) Transgenic Mice Does Not Alter The Proteolysis of APP, Levels of Amyloid-β or Pathologic Phenotype , 2016, PloS one.

[15]  Weiming Xia,et al.  Genomics of Alzheimer Disease: A Review. , 2016, JAMA neurology.

[16]  Charalambos P. Kyriacou,et al.  Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites , 2016, Proceedings of the National Academy of Sciences.

[17]  N. Belyaev,et al.  New Insights into Epigenetic and Pharmacological Regulation of Amyloid-Degrading Enzymes , 2016, Neurochemical Research.

[18]  Bengt Winblad,et al.  Loss of neprilysin alters protein expression in the brain of Alzheimer's disease model mice , 2015, Proteomics.

[19]  N. Greig,et al.  Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. , 2015, Current Alzheimer research.

[20]  J. Bockaert,et al.  Serotonin: A New Hope in Alzheimer's Disease? , 2015, ACS chemical neuroscience.

[21]  H. Tanila,et al.  APP intracellular domain derived from amyloidogenic β- and γ-secretase cleavage regulates neprilysin expression , 2015, Front. Aging Neurosci..

[22]  L. B. Snoek,et al.  Systemic Regulation of RAS/MAPK Signaling by the Serotonin Metabolite 5-HIAA , 2015, PLoS genetics.

[23]  R. Jope,et al.  Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. , 2015, Pharmacology & therapeutics.

[24]  F. Giorgini,et al.  The kynurenine pathway and neurodegenerative disease. , 2015, Seminars in cell & developmental biology.

[25]  C. Mathis,et al.  γ-Hydroxybutyrate (Xyrem) ameliorates clinical symptoms and neuropathology in a mouse model of Alzheimer's disease , 2015, Neurobiology of Aging.

[26]  P. Deyn,et al.  Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease , 2014, Neurobiology of Aging.

[27]  S. Knapp,et al.  A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics , 2014, Nature chemical biology.

[28]  N. Belyaev,et al.  The Aβ‐clearance protein transthyretin, like neprilysin, is epigenetically regulated by the amyloid precursor protein intracellular domain , 2014, Journal of neurochemistry.

[29]  Young Chul Youn,et al.  The genetics of Alzheimer’s disease , 2014, Clinical interventions in aging.

[30]  V. Kemmel,et al.  Gamma-hydroxybutyrate, acting through an anti-apoptotic mechanism, protects native and amyloid-precursor-protein-transfected neuroblastoma cells against oxidative stress-induced death , 2014, Neuroscience.

[31]  Zheng Wang,et al.  Valproic Acid Reduces Neuritic Plaque Formation and Improves Learning Deficits in APPSwe/PS1A246E Transgenic Mice via Preventing the Prenatal Hypoxia‐Induced Down‐Regulation of Neprilysin , 2014, CNS neuroscience & therapeutics.

[32]  Jong-sang Park,et al.  Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer's disease mice , 2013, Brain Research.

[33]  F. Bihel,et al.  The neuroprotector kynurenic acid increases neuronal cell survival through neprilysin induction , 2013, Neuropharmacology.

[34]  J. Fine,et al.  Intranasal administration of CNS therapeutics to awake mice. , 2013, Journal of visualized experiments : JoVE.

[35]  C. Mathis,et al.  Detecting spatial memory deficits beyond blindness in tg2576 Alzheimer mice , 2013, Neurobiology of Aging.

[36]  Sandro Sorbi,et al.  Genetics of familial and sporadic Alzheimer's disease. , 2013, Frontiers in bioscience.

[37]  M. Rattray,et al.  Gene expression profiling in human neurodegenerative disease , 2012, Nature Reviews Neurology.

[38]  H. Nawa,et al.  Cell Surface Expression of the Major Amyloid-β Peptide (Aβ)-degrading Enzyme, Neprilysin, Depends on Phosphorylation by Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase (MEK) and Dephosphorylation by Protein Phosphatase 1a* , 2012, The Journal of Biological Chemistry.

[39]  N. Belyaev,et al.  Are amyloid‐degrading enzymes viable therapeutic targets in Alzheimer’s disease? , 2012, Journal of neurochemistry.

[40]  D. I. Lewis,et al.  Effect of Sodium Valproate Administration on Brain Neprilysin Expression and Memory in Rats , 2012, Journal of Molecular Neuroscience.

[41]  Dietmar R. Thal,et al.  Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.

[42]  Sanjeev Gupta,et al.  Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders , 2011, Journal of cellular and molecular medicine.

[43]  M. Mintun,et al.  Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans , 2011, Proceedings of the National Academy of Sciences.

[44]  R. Marr,et al.  Intranasal Phosphoramidon Increases Beta-Amyloid Levels in Wild-Type and NEP/NEP2-Deficient Mice , 2011, Journal of Molecular Neuroscience.

[45]  Kanae Iijima-Ando,et al.  Transgenic Drosophila models of Alzheimer’s disease and tauopathies , 2010, Brain Structure and Function.

[46]  R. Nitrini,et al.  The dorsal raphe nucleus shows phospho‐tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset? , 2009, Neuropathology and applied neurobiology.

[47]  D. Michaelson,et al.  Activation of the Amyloid Cascade by Intracerebroventricular Injection of the Protease Inhibitor Phosphoramidon , 2008, Neurodegenerative Diseases.

[48]  M. Good,et al.  The "Swedish" mutation of the amyloid precursor protein (APPswe) dissociates components of object-location memory in aged Tg2576 mice. , 2007, Behavioral neuroscience.

[49]  A. Jochemsen,et al.  Multiple neurotoxic stresses converge on MDMX proteolysis to cause neuronal apoptosis , 2007, Cell Death and Differentiation.

[50]  E. Nestler,et al.  The many faces of CREB , 2005, Trends in Neurosciences.

[51]  M. Higuchi,et al.  Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation , 2005, Nature Medicine.

[52]  G. Laviola,et al.  Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer’s disease , 2005, Behavioural Brain Research.

[53]  George A. Carlson,et al.  The Relationship between Aβ and Memory in the Tg2576 Mouse Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[54]  S. Younkin,et al.  The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[55]  C. Eckman,et al.  Degradation of the Alzheimer's Amyloid β Peptide by Endothelin-converting Enzyme* , 2001, The Journal of Biological Chemistry.

[56]  H. Braak,et al.  The evolution of Alzheimer's disease‐related cytoskeletal pathology in the human raphe nuclei , 2000, Neuropathology and applied neurobiology.

[57]  U. Gärtner,et al.  Elevated expression of p21ras is an early event in Alzheimer's disease and precedes neurofibrillary degeneration , 1999, Neuroscience.

[58]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[59]  R. Heumann,et al.  Induction of p21ras in Alzheimer pathology. , 1995, Neuroreport.